October 27, 2017 / 11:18 AM / a month ago

Shire delivers Q3 earnings beat, reiterates guidance

LONDON, Oct 27 (Reuters) - London-listed pharmaceutical firm Shire reported a 20 percent rise in third-quarter earnings, beating market expectations, driven by growth in its immunology franchise.

The company posted non-GAAP earnings per share, its preferred measure, of $3.81 on total revenue of $3.70 billion on Friday, and reiterated its guidance for the year.

Analysts on average expected the company to report earnings per share of $3.69 on revenue of $3.75 billion for the third quarter.

​ (Reporting by Paul Sandle; editing by Kate Holton)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below